Skip to main content
Livermore
Livermore
ZHEN

Sectoral Asset Management Inc

SEC CIK
0001274413
Latest filing
Aug 14, 2026

The latest 13F from Sectoral Asset Management Inc covers Q2 2026 (filed Aug 14, 2026): 82 long positions worth $143.3M. The top 10 holdings make up 39.6% of the portfolio, and the largest is Contineum Therapeutics, Inc. (CTNM) at 8.3%. Livermore has 22 filings on Form 13F from this institution, going back to Q1 2021.

What changed in Q2 2026

Share counts compared with Q1 2026: how many positions were new, added to, reduced or sold out, and the biggest buys and sells. Dollar amounts are estimated at the quarter-end prices implied by the filing.

Full comparison
New
14
Est. +$23.2M
Added
17
Est. +$16.7M
Reduced
18
Est. −$7.28M
Sold out
9
Est. −$17.6M

Top 5 holdings

Share of this quarter's portfolio value

  1. CTNMContineum Therapeutics, Inc.
    8.3%$11.9MHistory
  2. SIShoulder Innovations, Inc.
    6.1%$8.73MHistory
  3. LLYEli Lilly & Co
    5.3%$7.62MHistory
  4. UNHUnitedHealth Group Inc
    3.8%$5.50MHistory
  5. JNJJohnson & Johnson
    3.2%$4.63MHistory

Share of portfolio

Top 5 holdings and the other 77 positions, by share of portfolio value

  1. CTNM8.3%
  2. SI6.1%
  3. LLY5.3%
  4. UNH3.8%
  5. JNJ3.2%
  6. Other 77 positions73.2%

Biggest buys

New and added positions, by estimated amount bought

  1. ORKAOruka Therapeutics, Inc.
    +$4.00MNewHistory
  2. DFTXDefinium Therapeutics, Inc.
    +$3.68MNewHistory
  3. IRTCiRhythm Holdings, Inc.
    +$3.10MNewHistory
  4. AVTXAvalo Therapeutics, Inc.
    +$2.22MNewHistory
  5. SMMTSummit Therapeutics Inc.
    +$2.19MAddedHistory

Largest weight increases

New and added positions, by percentage points of the portfolio gained

  1. ORKAOruka Therapeutics, Inc.
    +2.79 pp0.0% → 2.8%History
  2. DFTXDefinium Therapeutics, Inc.
    +2.57 pp0.0% → 2.6%History
  3. IRTCiRhythm Holdings, Inc.
    +2.16 pp0.0% → 2.2%History
  4. AVTXAvalo Therapeutics, Inc.
    +1.55 pp0.0% → 1.5%History
  5. RCUSArcus Biosciences, Inc.
    +1.53 pp0.9% → 2.4%History

Biggest sells

Reduced and sold-out positions, by estimated amount sold

  1. EVMNEvommune, Inc.
    −$13.5MSold outHistory
  2. GILDGilead Sciences, Inc.
    −$868.0KReducedHistory
  3. RAPPRapport Therapeutics, Inc.
    −$835.0KSold outHistory
  4. VRTXVertex Pharmaceuticals Inc
    −$782.3KReducedHistory
  5. BOLDBoundless Bio, Inc.
    −$746.4KSold outHistory

Largest weight decreases

Reduced and sold-out positions, by percentage points of the portfolio lost

  1. EVMNEvommune, Inc.
    −11.22 pp11.2% → 0.0%History
  2. GILDGilead Sciences, Inc.
    −1.60 pp3.4% → 1.8%History
  3. REGNRegeneron Pharmaceuticals, Inc.
    −1.11 pp2.1% → 0.9%History
  4. ABTAbbott Laboratories
    −1.03 pp2.2% → 1.1%History
  5. VRTXVertex Pharmaceuticals Inc
    −0.98 pp2.9% → 1.9%History

Metrics

13F metrics for Q2 2026, computed only from the numbers in the filings. Definitions below.

Portfolio value
$143.3M
+$22.6M (+18.7%) vs. prior quarter
Positions
82
+5 vs. prior quarter
Top 10 concentration
39.6%
Top 10 as share of value
Turnover
18.8%
Q2 2026, one quarter
Average holding period
12.0 quarters
Weighted by value

How these are calculated

  • Portfolio value: the market value of all long positions in the 13F, as reported at quarter end, excluding options.
  • Top 10 concentration: the combined value of the 10 largest positions as a share of portfolio value.
  • Turnover: the smaller of this quarter's estimated purchases and estimated sales, divided by the average of this and last quarter's portfolio value. Estimates multiply the change in shares by the quarter-end price implied by the filing (market value divided by shares); new positions use this quarter's value and sold-out positions last quarter's. Only positions reported in shares count, and it is not calculated when the previous quarter was not filed.
  • Average holding period: how many consecutive quarters each current position has been held (including this one; a quarter without the position or without a filing starts the count over), weighted by this quarter's value. Counting starts with the first 13F in Livermore (Q1 2021), so positions held before then are understated.

13F filings by quarter

22 quarters, going back to Q1 2021. Bars show each quarter's 13F portfolio value; quarters without a filing are left blank.

Peak $1.32B (Q1 2021)

Q1 2021: $1.32BQ2 2021: $1.24BQ3 2021: $1.20BQ4 2021: $664.4MQ1 2022: $563.3MQ2 2022: $496.3MQ3 2022: $507.6MQ4 2022: $516.8MQ1 2023: $520.3MQ2 2023: $599.8MQ3 2023: $513.5MQ4 2023: $232.2MQ1 2024: $254.4MQ2 2024: $246.1MQ3 2024: $169.3MQ4 2024: $149.8MQ1 2025: $128.5MQ2 2025: $151.5MQ3 2025: $162.0MQ4 2025: $124.8MQ1 2026: $120.7MQ2 2026: $143.3M
Q1 2021Q2 2026
13F filings of Sectoral Asset Management Inc by quarter
QuarterFiledPositionsValueTop 3 holdingsChangesFiling
Q2 2026Aug 14, 202682$143.3MCTNMSILLYvs. Q1 2026SEC
Q1 2026May 15, 202677$120.7MEVMNCTNMSIvs. Q4 2025SEC
Q4 2025Feb 9, 202674$124.8MEVMNCTNMLLYvs. Q3 2025SEC
Q3 2025Nov 14, 202582$162.0MCTNMLLYGPCRvs. Q2 2025SEC
Q2 2025Aug 14, 202594$151.5MLENZLLYUNHvs. Q1 2025SEC
Q1 2025May 15, 202584$128.5MLENZLLYUNHvs. Q4 2024SEC
Q4 2024Feb 14, 202586$149.8MLENZCTNMLLYvs. Q3 2024SEC
Q3 2024Nov 14, 202490$169.3MLENZCTNMLLYvs. Q2 2024SEC
Q2 2024Aug 13, 202497$246.1MLLYLENZCTNMvs. Q1 2024SEC
Q1 2024May 14, 202492$254.4MLENZLLYBOLDvs. Q4 2023SEC
Q4 2023Feb 14, 2024104$232.2MLLYUNHMRKvs. Q3 2023SEC
Q3 2023Nov 14, 2023123$513.5MBMRNLLYOPCHvs. Q2 2023SEC
Q2 2023Aug 11, 2023121$599.8MRCMEVHPRVAvs. Q1 2023SEC
Q1 2023May 12, 2023118$520.3MEVHRCMSWAVvs. Q4 2022SEC
Q4 2022Feb 10, 2023120$516.8MEVHHQYRCMvs. Q3 2022SEC
Q3 2022Nov 10, 2022109$507.6MUNHHQYBMRNvs. Q2 2022SEC
Q2 2022Aug 15, 2022112$496.3MUNHHQYRCMvs. Q1 2022SEC
Q1 2022May 10, 2022106$563.3MUNHHQYNARIvs. Q4 2021SEC
Q4 2021Feb 11, 2022108$664.4MARNAEFTROCDXvs. Q3 2021SEC
Q3 2021Nov 15, 2021127$1.20BEFTREVHSYNHvs. Q2 2021SEC
Q2 2021Aug 16, 2021127$1.24BTFXEVHATRCvs. Q1 2021SEC
Q1 2021May 14, 2021113$1.32BAVIREVHNVAX–SEC

13D and 13G filings

Companies where Sectoral Asset Management Inc reports owning 5% or more on Schedule 13D or 13G, and its latest filings.

Current stakes of 5% or more

Sectoral Asset Management Inc does not currently report owning 5% or more of any company.

Latest filings

8 filings on file made by Sectoral Asset Management Inc or listing it as a reporting person, newest first.

Schedule 13D and 13G filings by Sectoral Asset Management Inc
CompanyFiled (ET)FormStakeChangeEvent dateFiling
CTNMContineum Therapeutics, Inc.Feb 14, 202510:50 AM ET13G/A4.99%950.8K shares–Below 5%Dec 31, 2024SEC
CTNMContineum Therapeutics, Inc.Nov 14, 202413GOld format–New–SEC
GRTXGalera Therapeutics, Inc.Feb 14, 202413G/AOld format–––SEC
EFTReFFECTOR Therapeutics, Inc.Feb 14, 202413G/AOld format–––SEC
EFTReFFECTOR Therapeutics, Inc.Feb 13, 202313G/AOld format–––SEC
GRTXGalera Therapeutics, Inc.Feb 13, 202313GOld format–New–SEC
EFTReFFECTOR Therapeutics, Inc.Feb 11, 202213GOld format–New–SEC
APREAprea Therapeutics, Inc.Feb 12, 202113G/AOld format–––SEC